GAiT is an international resource to facilitate the therapeutic use of immunogenetically matched, clinical-grade new types of stem cells (iPSCs) for the benefit of patients globally. GAiT’s vision is that patients globally will have equity of access to this new generation of iPSC-derived cell therapy products.
GAiT’s mission is to enable the global human community the opportunity to benefit from the new generation of cell therapies by facilitating the development of, and access to, clinical-grade and haplotyped induced pluripotent stem cells for the manufacture of cell therapy products.
- Achieve consensus on donor selection and screening criteria and consent standards.
- Achieve global consensus on manufacturing and quality parameters and standards required to consider an iPSC line to be of clinical grade and develop an external quality assurance scheme to facilitate the development of comparability between centres.
- Gain agreement with regulators in various jurisdictions as to the acceptability of the quality standards proposed.
- Develop a database of clinical grade iPSC lines.
News & Events
The latest from GAiT
What is a target product profile (TPP) and why should you have one for you CAR T-cell therapy? A guest blogger from @CCRM_au explains. https://www.signalsblog.ca/target-product-profile-starting-that-journey-of-a-thousand-miles-with-the-right-first-step/
We want safe and efficacious iPSC therapeutics that have clinical impact globally. Is Quality Testing consistent and indicative for your "clinical-grade" iPSCs? GAiT & @CiRA_F_J conduct iPSC Quality Assessment Rounds to assist efficient translation.
At day 2 of the iPSC Manufacturing Summit, GAiT is chairing this morning's session entitled "Developing iPSC Differentiation to Efficently Create the Desired Cell Type".
iPSC Manufacturing Summit 2022
Join us in Boston for the iPSC Manufacturing Summit, the only forum dedicated to optimizing the scalable manufacture...
GAiT is happy to chair this morning's session entitled "Equipping iPSC Expansion Practices to Cater for Scale-Up & Commercialization" at the iPSC Manufacturing Summit http://www.ipsc-manufacturing-summit.com
iPSC Quality Round Participants have received automated emails regarding manuscript submission this week. We would be grateful if you can respond to these. If you have already done so, thank you.